BIRC5 and cancer: The net outcome of PRMT5‐induced epigenetic silencing is to promote growth and survival of cancer cell, which renders its ideal for therapeutic intervention, because its selective inhibition is marked by decreased expression of pro‐survival proteins, CYCLIN D1 and SURVIVIN. These molecular changes trigger reduced proliferation, migration and invasion, and increased cell death, which are all desired attributes for killing tumour cells.